EyePoint [EYPT] vs Vertex [VRTX] Detailed Stock Comparison

EyePoint Pharmaceuticals Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: EyePoint Pharmaceuticals Inc. wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 16 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric EyePoint Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -4.34 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 3.73 5.92 EyePoint Pharmaceuticals Inc.
Debt-to-Equity Ratio 46.82 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -0.16 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -5.31 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 93.41% 32.94% EyePoint Pharmaceuticals Inc.
Operating Margin (TTM) -450.66% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -72.19% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -38.89% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-243.39M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 87.57% 1.24% EyePoint Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 36.62 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.28B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 40.79 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 39.52% 85.39% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.17 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.91 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 18.97% 1.78% Vertex Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

EYPT
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
EyePoint Pharmaceuticals Inc.-1.52%-6.23%-10.90%-32.64%-15.01%-29.41%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
EyePoint Pharmaceuticals Inc.87.57%127.09%48.25%-61.31%-68.78%-92.75%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: EyePoint Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricEYPTVRTX
Market Information
Market Cap i$1.15B$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i863,4901,057,061
90 Day Avg. Volume i939,2471,272,097
Last Close$12.34$428.34
52 Week Range$7.35 - $19.11$362.50 - $507.92
% from 52W High-35.43%-15.67%
All-Time High$485.60 (Jan 24, 2005)$519.88 (Nov 04, 2024)
% from All-Time High-97.46%-17.61%
Growth Metrics
Quarterly Revenue Growth1.62%0.10%
Quarterly Earnings Growth-0.95%0.31%
Financial Health
Profit Margin (TTM) i0.93%0.33%
Operating Margin (TTM) i-4.51%0.40%
Return on Equity (TTM) i-0.72%0.23%
Debt to Equity (MRQ) i46.8210.91
Cash & Liquidity
Book Value per Share (MRQ)$3.70$73.49
Cash per Share (MRQ)$0.48$26.01
Operating Cash Flow (TTM) i$-240,110,000$3.63B
Levered Free Cash Flow (TTM) i$-148,239,872$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: EyePoint Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricEYPT (Apr 26, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-4.3428.40
Forward P/E i-4.9219.95
PEG Ratio i-0.160.88
Price to Sales (TTM) i36.629.22
Price to Book (MRQ) i3.735.92
Market Capitalization
Market Capitalization i$1.15B$109.45B
Enterprise Value i$1.28B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i40.798.83
Enterprise to EBITDA i-5.3121.78
Risk & Other Metrics
Beta i1.910.37
Book Value per Share (MRQ) i$3.70$73.49

Financial Statements Comparison: EyePoint Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEYPT (2025)VRTX (2025)
Revenue/Sales i31.37M12.00B
Cost of Goods Sold i2.07M1.65B
COGS % of Revenue i6.6%13.8%
Gross Profit i29.31M10.35B
Gross Margin i93.4%86.2%
Research & Development i221.04M4.04B
Operating Income (EBIT) i-243.43M4.55B
Operating Margin i-776.0%37.9%
EBITDA i-229.34M5.25B
EBITDA Margin i-731.1%43.7%
Pre-Tax Income i-231.68M4.64B
Pre-Tax Income % of Revenue i-738.5%38.7%
Income Tax i279,000690.00M
Income Tax % of Revenue i0.9%5.7%
Net Income (Profit) i-231.96M3.95B
Profit Margin i-739.4%32.9%

Balance Sheet & Liquidity Metrics

MetricEYPT (2025)VRTX (2025)
Cash & Equivalents i101.82M5.08B
Total Current Assets i328.66M11.20B
Total Current Assets % of Revenue i1,047.6%93.3%
Total Current Liabilities i37.02M3.86B
Total Current Liabilities % of Revenue i118.0%32.2%
Long-Term Debt i20.77M1.95B
Long-Term Debt % of Revenue i66.2%16.3%
Total Shareholders Equity i306.11M18.67B
Retained Earnings i-1.10B13.56B
Retained Earnings % of Revenue i-3,522.3%113.0%
Property, Plant & Equipment i29.62M1.56B

Cash Flow Statement Comparison

MetricEYPT (2025)VRTX (2025)
Operating Cash Flow i-244.79M3.77B
Operating Cash Flow % of Revenue i-780.3%31.4%
Capital Expenditures i-3.13M-437.60M
Free Cash Flow i-243.39M3.19B
FCF Margin i-775.8%26.6%
Debt Repayment i-105,000-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricEYPTVRTX
Shares Short i13.66M4.02M
Short Ratio i14.692.80
Short % of Float i18.97%1.78%
Shares Outstanding i82.83M253.99M
Float Shares i65.60M253.24M
% Held by Insiders i2.67%0.21%
% Held by Institutions i104.44%97.60%
% Held by Public i-7.11%2.19%

Dividend Analysis & Yield Comparison: EyePoint Pharmaceuticals Inc. vs Vertex Pharmaceuticals Inc.

MetricEYPTVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A